Thongsepee Nattaya, Amonyingcharoen Sumet, Chamod Pholasit, Himakhun Wanwisa, Sangpairoj Kant, Martviset Pongsakorn, Chantree Pathanin, Sornchuer Phornphan
Department of Preclinical Science, Faculty of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.
Thammasat University Research Unit in Nutraceuticals and Food Safety, Faculty of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.
BMC Complement Med Ther. 2025 Feb 27;25(1):85. doi: 10.1186/s12906-025-04836-8.
Kratom (Mitragyna speciosa), a plant native to Southeast Asia, is commonly used as a supplement for fatigue, pain relief, mood enhancement, and euphoria. Kratom extract exhibits diverse pharmacological properties, including antioxidant, anti-inflammatory, and gastrointestinal effects, with studies showing its ability to modulate gut microbiota and stimulate beneficial bacteria growth. Given these properties, kratom treatment may produce significant effects in a rat model, warranting further investigation.
Male Wistar rats were administered kratom extract orally on a daily basis for 28 days. Fresh fecal samples were collected and analyzed for changes in gut microbiome composition using 16S rRNA sequencing. Hematological parameters and lipid profiles were also measured to evaluate any systemic effects.
The administration of kratom extract did not significantly affect hematological parameters or lipid profiles. However, notable changes were observed in gut microbiota composition, with significant increases in specific bacteria such as Candidatus Stoquefichus and Prevotellaceae UCG-001, and a decrease in Corynebacterium. LEfSe and cladogram analyses corroborated the higher prevalence of Candidatus Stoquefichus, Prevotellaceae UCG-001, and Erysipelatoclostridiaceae in the kratom treatment group compared to controls.
Kratom extract significantly alters gut microbiome composition in rats, promoting beneficial bacteria while also elevating certain taxa associated with negative health outcomes. These mixed effects highlight the need for further research on the long-term implications of kratom use for gut health and its broader health consequences, as well as potential therapeutic applications.
Not applicable.
kratom(Mitragyna speciosa)是一种原产于东南亚的植物,通常用作缓解疲劳、止痛、改善情绪和产生欣快感的补充剂。kratom提取物具有多种药理特性,包括抗氧化、抗炎和胃肠道作用,研究表明其能够调节肠道微生物群并刺激有益细菌生长。鉴于这些特性,kratom治疗可能在大鼠模型中产生显著效果,值得进一步研究。
雄性Wistar大鼠每天口服kratom提取物,持续28天。收集新鲜粪便样本,使用16S rRNA测序分析肠道微生物组组成的变化。还测量了血液学参数和血脂谱,以评估任何全身效应。
给予kratom提取物对血液学参数或血脂谱没有显著影响。然而,在肠道微生物群组成中观察到显著变化,特定细菌如暂定斯托克菲奇菌属(Candidatus Stoquefichus)和普雷沃氏菌科UCG-001显著增加,棒状杆菌属减少。线性判别分析效应大小(LEfSe)和进化分支图分析证实,与对照组相比,kratom治疗组中暂定斯托克菲奇菌属、普雷沃氏菌科UCG-001和丹毒丝菌科的患病率更高。
kratom提取物显著改变大鼠肠道微生物组组成,促进有益细菌生长,同时也增加了某些与负面健康结果相关的分类群。这些混合效应凸显了需要进一步研究kratom使用对肠道健康的长期影响及其更广泛的健康后果,以及潜在的治疗应用。
不适用。